Z-VAD-FMK

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis. (In Vitro) :Z-VAD (OMe) -FMK (Z-Val-Ala-Asp (OMe) -FMK) is a broad-spectrum caspase inhibitor, has been shown to inhibit the intracellular activation of caspase-like proteases. The injection of Z-VAD (OMe) -FMK suppresses the caspase-3 activity in lung tissues, and significantly decreases the number of terminal dUTP nick-end labeling-positive cells. Z-VAD (OMe) -FMK effectively inhibits UCHL1's reaction with hemagglutinin-tagged ubiquitin vinylmethyl ester (HA-UbVME) at the concentration of 100 μM. Z-VAD (OMe) -FMK is administered intraperitoneally at 1 hour before and 6 hours after SAH. Expression of caspase-3 and positive TUNEL is examined as markers for apoptosis. Z-VAD (OMe) -FMK suppresses TUNEL and caspase-3 staining in endothelial cells, decreases caspase-3 activation, reduces BBB permeability, relieves vasospasm, abolishes brain edema, and improves neurological outcome. Z-VAD (OMe) -FMK is a cell-permeable caspase inhibitor, efficiently blocks cell death induced by SMN deficiency. (In Vivo) :The survival rate of mice is prolonged significantly by the injection of Z-VAD (OMe) -FMK (Z-Val-Ala-Asp (OMe) -FMK) . All mice succumbed to LPS within 30 hours. By contrast, the mice treated with Z-VAD (OMe) -FMK survive significantly longer and 27% of the mice survived more than 7 days.